New drug combo aims to shrink skin cancer before surgery
NCT ID NCT06418724
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests two drugs, cemiplimab and cetuximab, given before surgery to people with advanced skin cancer that is hard to remove. The goal is to shrink the tumor enough to make surgery easier or even unnecessary. The study will enroll 27 participants across three sites in Australia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cemiplimab and cetuximab (drugs that help the immune system attack cancer and block a growth signal)
- What this could lead to
- If successful, this combination could shrink advanced skin cancers before surgery, making them easier to remove or even avoiding surgery altogether.
- What could go wrong
- This is a small, early-phase trial with only 27 participants. The combination may cause significant side effects, and it is not yet known if it will improve long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.